Not all patients with heart failure can be stabilized with oral guideline-directed medical therapy alone. In acute decompensated HF with hemodynamic compromise, and in advanced HF refractory to maximally optimized guideline-directed medical therapy (GDMT), pharmacological support of cardiac function and systemic perfusion becomes necessary. This module covers three distinct categories of agents: digoxin: a positive inotrope with a unique neurohormonal mechanism and a narrow therapeutic index that places it in a carefully circumscribed clinical niche; intravenous positive inotropes (dobutamine and milrinone): agents that augment cardiac output in low-output states at the cost of increased myocardial oxygen demand and proarrhythmia; and vasopressors (norepinephrine, dopamine, vasopressin): agents used to maintain systemic perfusion pressure in cardiogenic shock. The clinical decision-making framework for advanced HF pharmacotherapy is inseparable from an understanding of hemodynamic phenotypes, which determines whether a given patient requires vasodilation, diuresis, inotropy, vasopressor support, or mechanical circulatory assistance.
Digoxin is a cardiac glycoside derived from Digitalis lanata. Its primary molecular target is the Na-K-ATPase pump on the myocyte cell membrane, which it inhibits reversibly.1 Inhibition of Na-K-ATPase reduces the outward sodium gradient that drives the Na-Ca exchanger (NCX) in its forward mode (3 Na⁺ in, 1 Ca2⁺ out). With less NCX-driven calcium efflux, intracellular calcium rises, increasing sarcoplasmic reticulum calcium stores and augmenting the calcium transient available for myofilament activation during each systole.1 The result is a modest but measurable increase in contractile force (positive inotropy) without increasing myocardial oxygen consumption proportionately: an important distinction from catecholamine-based inotropes, which increase both contractility and oxygen demand. Digoxin also exerts important neurohormonal effects: it enhances vagal tone (negative chronotropy and dromotrophy through enhanced acetylcholine sensitivity at the SA and AV nodes) and reduces sympathetic nerve traffic to the heart and periphery: effects that are relevant at lower serum concentrations than those required for positive inotropy and which are now considered its primary mechanism of clinical benefit in HF.1
The Digitalis Investigation Group (DIG) trial (1997) remains the definitive evidence for digoxin in heart failure with reduced ejection fraction (HFrEF).2 6,800 patients with HFrEF (left ventricular ejection fraction (LVEF) ≤45%, sinus rhythm, on background ACEi and diuretics) were randomized to digoxin vs. placebo. The primary finding: digoxin did not reduce all-cause mortality (HR 0.99; 95% CI 0.91–1.07; p=0.80). However, digoxin significantly reduced the composite of HF-related death or HF hospitalization (RR 0.75; p<0.001), and reduced all-cause hospitalizations.2 A prespecified subgroup analysis demonstrated that higher serum digoxin concentrations (>1.2 ng/mL) were associated with increased mortality, particularly in women, while lower concentrations (0.5–0.9 ng/mL) were associated with a trend toward mortality reduction. This finding repositioned digoxin as a drug to be used at the lowest effective concentration rather than at traditional "therapeutic" levels.2 Current guidelines target a serum digoxin concentration of 0.5–0.9 ng/mL for HF; the upper limit of the traditional "therapeutic range" (2.0 ng/mL) is now considered excessive and potentially harmful. 2022 AHA/ACC/HFSA guidelines give digoxin a Class IIb recommendation for HFrEF patients in sinus rhythm who remain symptomatic (NYHA class II–IV) despite optimized GDMT, with the primary benefit of reducing HF hospitalizations rather than improving mortality.3
Digoxin's vagotonic properties slow AV nodal conduction and reduce the ventricular rate in AF. At rest, digoxin provides reasonable rate control; however, during exercise or sympathetic activation, the rate-slowing effect is significantly attenuated (because the mechanism is vagal, not direct AV nodal blockade), making it less effective than beta-blockers for dynamic rate control.1 Current guidelines recommend beta-blockers as the first-line rate control agent in AF with HFrEF. Digoxin may be added as a second-line agent when rate control is insufficient on maximal beta-blocker, particularly in patients with very low blood pressure or in those with severe HF where beta-blocker up-titration is limited by hemodynamic tolerance.3
Digoxin has a narrow therapeutic index and highly variable pharmacokinetics, making monitoring essential.1 Volume of distribution is very large (~7 L/kg) due to extensive tissue binding (skeletal muscle, heart); this means that loading doses are needed to achieve therapeutic plasma levels promptly, and that plasma levels do not equilibrate with tissue levels for several hours after a dose. Half-life is approximately 36–48 hours in patients with normal renal function; digoxin is renally excreted (70%) without significant hepatic metabolism. In CKD, the half-life prolongs dramatically, requiring dose reduction and more frequent monitoring.1 Steady-state is reached after approximately five half-lives (7–10 days).
Loading (digitalizing) dose: Not typically used in chronic HF management; loading is reserved for urgent rate control in acute AF. In HF, starting at a maintenance dose and allowing steady-state to build over 1–2 weeks is safer. Maintenance dose: 0.125–0.25 mg daily for most patients. Use 0.0625 mg (62.5 mcg) every other day in elderly patients, those with CKD (eGFR <60), or very low body weight. Target serum concentration: 0.5–0.9 ng/mL.2 Check serum digoxin level at least 6–8 hours after the last dose to avoid the distribution phase, when levels are falsely elevated. Drug interactions: Multiple clinically significant interactions affect digoxin levels. Amiodarone, quinidine, verapamil, dronedarone, spironolactone, and clarithromycin increase digoxin levels: typically by 50–100%. When these drugs are added, the digoxin dose should be empirically halved and levels monitored. Drugs that reduce gut absorption (cholestyramine, antacids, kaolin-pectin) reduce digoxin levels. P-glycoprotein inducers (rifampicin, St. John's Wort) reduce digoxin bioavailability.1
Digoxin toxicity is among the most clinically important drug intoxications in cardiology, because it is common (narrow therapeutic index), often subtle in early stages, and can cause life-threatening arrhythmias. Risk factors: hypokalemia (the single most important predisposing factor: potassium and digoxin compete for the same binding site on Na-K-ATPase; hypokalemia sensitizes the myocardium to digoxin toxicity at any given plasma level), hypomagnesemia, hypothyroidism, older age, renal impairment, and concurrent drug interactions.1 Clinical features of digoxin toxicity: Non-cardiac: Nausea, vomiting, anorexia (very common, often preceding arrhythmias: useful early warning signs), visual disturbances (yellow-green discoloration of vision, halos around lights: caused by effects on retinal photoreceptors), fatigue, confusion in the elderly.
Cardiac arrhythmias: The classic pattern of digoxin toxicity combines enhanced automaticity (from intracellular calcium overload) with depressed conduction (from enhanced vagal tone and direct SA/AV nodal suppression). Specific arrhythmias: premature ventricular complexes (most common early finding), bidirectional ventricular tachycardia (highly specific for digoxin toxicity: alternating QRS complex (QRS) axis in VT), accelerated junctional rhythm, atrial tachycardia with AV block (paroxysmal atrial tachycardia (PAT) with block: the combination of increased atrial automaticity and reduced AV conduction is pathognomonic), ventricular fibrillation in severe toxicity. Bradyarrhythmias: sinus bradycardia, first-degree AV block, Wenckebach (Mobitz type I second-degree AV block), and complete heart block: all reflecting enhanced vagotonia.1
Management of digoxin toxicity: (1) Discontinue digoxin immediately. (2) Correct electrolyte abnormalities: aggressively correct hypokalemia (potassium supplementation IV if severe, even when K⁺ appears low-normal: the intracellular deficit is typically larger); correct hypomagnesemia. (3) Manage bradyarrhythmias: atropine for symptomatic bradycardia; temporary pacing for high-degree AV block unresponsive to atropine. (4) Manage ventricular arrhythmias: lidocaine or phenytoin are preferred over procainamide (which further depresses conduction); cardioversion is relatively contraindicated in digoxin-toxic arrhythmias (may precipitate intractable VF) unless absolutely life-threatening. (5) Digoxin-specific antibody fragments (Digibind, DigiFab): the definitive treatment for life-threatening toxicity. Each vial binds approximately 0.5 mg of digoxin. Dose is calculated based on the estimated total body load (plasma concentration × volume of distribution × body weight, or for acute massive ingestion, the amount ingested). After administration, total digoxin levels will be markedly elevated (measuring the drug-antibody complex), so digoxin levels are no longer interpretable for monitoring.1
Parenteral inotropic agents are used in two primary settings in HF: (1) acute hemodynamic decompensation with low cardiac output (cardiogenic shock or pre-shock with evidence of end-organ hypoperfusion); and (2) advanced HF refractory to all oral GDMT, where continuous or intermittent inotrope infusions serve as a bridge to device therapy (left ventricular assist device, LVAD) or heart transplant, or as palliative therapy to improve quality of life in patients not eligible for mechanical support.3
Pharmacology: Dobutamine is a synthetic catecholamine with primarily beta-1 adrenergic agonist activity and modest beta-2 and alpha-1 activity.5 Beta-1 stimulation increases heart rate (positive chronotropy) and contractility (positive inotropy) through increased cAMP production and PKA-mediated phosphorylation of L-type calcium channels and phospholamban. Beta-2 activity causes peripheral vasodilation. The net hemodynamic effect is increased cardiac output, modestly reduced systemic vascular resistance (SVR), and little change in heart rate at low doses (though tachycardia commonly occurs at higher doses).5 Dobutamine does not stimulate dopaminergic receptors.
Dosing: IV infusion, 2–20 mcg/kg/min. Start at 2–5 mcg/kg/min and titrate to hemodynamic response (target MAP ≥65 mmHg, adequate urine output, clearance of clinical signs of hypoperfusion). Does not require weight-adjusted dosing in obese patients for initial estimates. Limitations and risks: (1) Tachycardia and proarrhythmia: ventricular ectopy, atrial fibrillation, and sustained ventricular tachycardia are significant risks, particularly at higher doses. (2) Myocardial oxygen demand: beta-1 activation increases heart rate and contractility, both of which increase myocardial oxygen consumption: potentially harmful in the context of ischemic cardiomyopathy or coexistent coronary artery disease. (3) Tolerance: with continuous infusion beyond 72–96 hours, receptor downregulation reduces dobutamine's hemodynamic efficacy. (4) Mortality signal: observational and randomized data (including post-hoc analyses of the OPTIME-CHF trial) suggest that dobutamine may increase short-term mortality in acute HF when used outside of cardiogenic shock: reinforcing its use for hemodynamic rescue, not routine augmentation.5 (5) Hypotension: in patients with severe mitral regurgitation or marked vasodilation, the SVR-reducing beta-2 effect may cause hypotension despite increased cardiac output. Contraindications: Hypertrophic obstructive cardiomyopathy (HOCM): augmented inotropy worsens dynamic left ventricular outflow tract (LVOT) obstruction and can precipitate acute deterioration; severe tachyarrhythmia that would be worsened.
Pharmacology: Milrinone is a phosphodiesterase type 3 (PDE3) inhibitor.5 PDE3 degrades cAMP in both cardiac myocytes and vascular smooth muscle. By inhibiting PDE3, milrinone raises intracellular cAMP in both tissues, producing: (1) positive inotropy in the myocardium (cAMP-mediated calcium influx and phospholamban phosphorylation, independent of beta-adrenergic receptors); and (2) systemic and pulmonary vasodilation (cAMP-mediated smooth muscle relaxation).5 This vasodilatory action, which is not shared by dobutamine to the same degree, makes milrinone particularly useful in HF patients with elevated pulmonary vascular resistance, right ventricular failure, or afterload reduction needs. Milrinone's mechanism is receptor-independent, which means it retains efficacy in patients with downregulated beta-1 adrenergic receptors (a common feature of advanced HF): an advantage over dobutamine in this population.5 Pharmacokinetics: Eliminated primarily by the kidney (80–85% excreted unchanged in urine). Half-life approximately 2–3 hours in normal renal function, extending significantly in CKD. Requires dose reduction (loading dose and infusion rate) in patients with eGFR <50 mL/min/1.73m2.
Dosing: Optional loading dose 50 mcg/kg IV over 10 minutes (often omitted in hypotensive patients due to risk of acute vasodilation). Maintenance infusion: 0.125–0.75 mcg/kg/min. Lower doses (0.125–0.25 mcg/kg/min) are often used in advanced HF to minimize adverse effects. Limitations and risks: (1) Hypotension: milrinone's vasodilatory effects reduce both SVR and pulmonary vascular resistance: in patients with low baseline BP or relative hypovolemia, this can cause significant hypotension. Omitting the loading dose reduces this risk. (2) Proarrhythmia: like dobutamine, milrinone increases ventricular ectopy and the risk of sustained ventricular arrhythmias. (3) Renal sensitivity: requires careful dose adjustment in CKD; accumulation in renal failure amplifies both hemodynamic and arrhythmic risks. (4) Mortality signal: the OPTIME-CHF trial (2002) randomized 951 patients with acute decompensated HFrEF (not in cardiogenic shock) to milrinone vs. placebo; milrinone did not reduce hospitalizations and was associated with a significant increase in sustained hypotension and new atrial arrhythmias, without improvement in outcomes.4 This trial establishes that milrinone use should be limited to patients with hemodynamic compromise and afterload elevation, not routine acute decompensated HF.
The choice between dobutamine and milrinone depends on the clinical context: Right ventricular failure/pulmonary hypertension: Milrinone is preferred due to its more potent pulmonary vasodilatory effect: reducing RV afterload and improving right ventricular-pulmonary arterial coupling (RV-PA) coupling. Dobutamine has modest pulmonary effects.5 Post-cardiac surgery / transplant: Milrinone is commonly used post-cardiopulmonary bypass, where beta-adrenergic receptor downregulation renders dobutamine less effective. Concurrent beta-blocker use: Milrinone acts downstream of the beta receptor (at PDE3) and is not affected by beta-blocker-mediated receptor blockade. Dobutamine's efficacy is attenuated by beta-blockers. In patients on full-dose beta-blocker therapy who develop acute decompensation requiring inotropic support, milrinone is preferred.5 Renal impairment: Dobutamine is the preferred inotrope in patients with significant CKD, as milrinone accumulates in renal failure. Hypotension: Both can cause hypotension, but milrinone's vasodilatory effect is more pronounced and is more reliably associated with hypotension, especially without a loading dose omission. In the hypotensive patient without pulmonary hypertension, dobutamine may be preferable.
Ischemic heart disease: Neither inotrope is ideal in the context of active ischemia, as both increase myocardial oxygen demand. However, milrinone's vasodilatory effect may provide a modest reduction in afterload that offsets this somewhat. Beta-1 stimulation with dobutamine may be more problematic in severe coronary disease.
Levosimendan is a calcium sensitizer (not a conventional inotrope) that increases myocardial contractility by enhancing the calcium sensitivity of troponin C without raising intracellular calcium: thereby avoiding the adverse oxygen demand and arrhythmia risk associated with calcium-dependent inotropes.5 It also opens ATP-sensitive potassium channels in vascular smooth muscle, causing vasodilation. Levosimendan is approved in many countries (Europe, Latin America, Asia) for acute decompensated HF with low cardiac output but is not approved in the United States. Multiple trials (SURVIVE, REVIVE II) showed hemodynamic superiority to dobutamine but no significant mortality advantage.5 It is mentioned here as clinicians may encounter it in international practice.
Cardiogenic shock is defined by persistent hypotension (systolic blood pressure (SBP) <90 mmHg for >30 minutes or requiring vasopressors to maintain SBP ≥90 mmHg), with evidence of end-organ hypoperfusion despite adequate intravascular volume.5 Management combines hemodynamic resuscitation (vasopressors and/or inotropes), identification and treatment of the underlying cause, and consideration of mechanical circulatory support (MCS). The pharmacological goal in cardiogenic shock is to restore mean arterial pressure (MAP ≥65 mmHg) and tissue perfusion while minimizing further myocardial injury.
Mechanism: Norepinephrine is the endogenous sympathetic neurotransmitter with potent alpha-1 adrenergic agonism (marked arterial and venous vasoconstriction) and moderate beta-1 agonism (positive inotropy).5 The alpha-1-mediated increase in SVR raises MAP, restoring coronary perfusion pressure (diastolic BP is the primary determinant of coronary perfusion). Beta-1 stimulation provides modest inotropy. Beta-2 activity is minimal.
Role in cardiogenic shock: Norepinephrine is the vasopressor of choice in cardiogenic shock: supported by the SOAP II trial (2010), which demonstrated lower 28-day mortality compared to dopamine in cardiogenic shock (31% vs. 33%, non-significant overall, but the cardiogenic shock subgroup showed significantly higher 28-day mortality with dopamine vs. norepinephrine, p=0.03).7 Norepinephrine's reliable vasoconstrictive effect restores perfusion pressure without the excessive tachycardia associated with dopamine or pure beta-agonists. Dosing: IV infusion, 0.01–3 mcg/kg/min. Titrate to target MAP ≥65 mmHg. Requires central venous access (peripheral extravasation causes tissue necrosis). Monitor for end-organ perfusion: urine output, mental status, lactate clearance. Risks: Excessive vasoconstriction increasing LV afterload: a concern in cardiogenic shock where the already-failing LV faces higher resistance. This risk is mitigated when norepinephrine is combined with an inotropic agent (dobutamine or milrinone) to maintain cardiac output while MAP is supported.5 Reflex bradycardia is possible with pure alpha stimulation. Digital/mesenteric ischemia with prolonged high-dose infusion.
Pharmacology: Dopamine is an endogenous catecholamine precursor of norepinephrine with dose-dependent receptor specificity.5 At low doses (1–3 mcg/kg/min), dopamine stimulates dopaminergic receptors (D1/D2) in renal, mesenteric, and coronary vascular beds, causing vasodilation. "Renal-dose dopamine": the concept that low-dose dopamine selectively enhances renal perfusion and diuresis in cardiorenal syndrome: was evaluated in prospective randomized trials and found to be ineffective; this practice has been abandoned in guideline-directed HF care. At medium doses (3–10 mcg/kg/min), beta-1 effects predominate (inotropy, chronotropy). At high doses (>10 mcg/kg/min), alpha-1 effects dominate (vasoconstriction), similar to norepinephrine. Role in cardiogenic shock: Dopamine has largely been replaced by norepinephrine as the preferred vasopressor in cardiogenic shock, based on the SOAP II trial demonstrating greater arrhythmia burden (AF, ventricular ectopy) and a trend toward worse outcomes in cardiogenic shock with dopamine vs. norepinephrine.5 Dopamine may still be used when a combined inotrope-vasopressor effect is desired and norepinephrine + dobutamine combination is not preferred or available.
Mechanism: Vasopressin (arginine vasopressin, ADH) acts on V1a receptors in vascular smooth muscle, causing potent vasoconstriction independent of adrenergic receptors.5 This receptor-independent mechanism is the basis for its use as a second-line vasopressor in vasodilatory (septic) shock: and occasionally in cardiogenic shock with a vasodilatory component (e.g., post-cardiotomy vasoplegic syndrome, LVAD-supported patients with persistently low SVR). Vasopressin is also used at low doses (0.03–0.04 units/min, fixed dose) to augment MAP in mixed shock states, allowing norepinephrine dose reduction. Dosing in shock: 0.01–0.04 units/min, typically used as a fixed dose rather than titrated. Doses above 0.04 units/min are associated with coronary, digital, and mesenteric ischemia.
Epinephrine stimulates beta-1, beta-2, and alpha-1 receptors, producing potent inotropy, chronotropy, and vasoconstriction.5 In cardiogenic shock, epinephrine may be used when combined inotrope-vasopressor effects are needed and norepinephrine + dobutamine is insufficient. However, epinephrine causes marked tachycardia, significant lactic acidosis (through beta-2-mediated aerobic glycolysis), and substantially increased myocardial oxygen demand: making it a last-resort agent in cardiogenic shock. The OPTIMA CC trial compared epinephrine to norepinephrine + dobutamine in cardiogenic shock and found comparable hemodynamic effects but more adverse metabolic effects with epinephrine, and the trial was stopped early due to an excess of refractory shock in the epinephrine arm.5
Mechanical circulatory support (MCS) devices do not replace pharmacological management of advanced HF but interact with it in clinically important ways. The clinician managing a patient on MCS must understand how device support alters the pharmacological milieu.
The IABP improves coronary perfusion through diastolic counterpulsation (balloon inflation in diastole augments aortic diastolic pressure and coronary perfusion) and reduces LV afterload through systolic deflation.6 Pharmacological implication: IABP support may allow norepinephrine and inotrope doses to be reduced, reducing the risks of vasoconstriction and tachycardia. The IABP-SHOCK II trial (2012) did not demonstrate a 30-day mortality benefit of routine IABP in cardiogenic shock complicating MI over optimal pharmacological therapy alone: but IABP remains commonly used in clinical practice for hemodynamic stabilization during intervention.6
Impella devices provide direct LV unloading through an axial flow pump that draws blood from the LV and ejects it into the aorta. VA-ECMO provides complete cardiopulmonary bypass support. Pharmacological implications: (1) On VA-ECMO, reduced LV ejection due to retrograde aortic flow may require inotropic support to prevent LV distension and pulmonary edema; (2) Anticoagulation management (heparin, bivalirudin) is critical; (3) Inotropes and vasopressors can generally be weaned as MCS support is established, providing myocardial rest.6
In patients with advanced HFrEF not eligible for MCS or transplant, continuous or intermittent home inotrope infusions (dobutamine or milrinone) may be used as destination therapy for symptom palliation.3 This is a Class IIb recommendation in patients with NYHA class IV symptoms refractory to all oral GDMT who are not candidates for MCS or transplant and who have an understanding of the palliative intent.3 These infusions do not extend survival, indeed, they may shorten it through proarrhythmia, but they can substantially improve quality of life, functional capacity, and reduce the burden of recurrent HF hospitalizations in terminal HF. Clear communication of the goals-of-care context is essential before initiating palliative inotrope therapy.
Gheorghiade M, van Veldhuisen DJ, Colucci WS. Contemporary use of digoxin in the management of cardiovascular disorders. Circulation. 2006;113(21):2556–2564
doi:10.1161/CIRCULATIONAHA.105.560110The Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure (DIG trial). N Engl J Med. 1997;336(8):525–533
doi:10.1056/NEJM199702203360801Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure. J Am Coll Cardiol. 2022;79(17):e263–e421
doi:10.1016/j.jacc.2021.12.012Cuffe MS, Califf RM, Adams KF, et al. Short-term intravenous milrinone for acute exacerbation of chronic heart failure (OPTIME-CHF). JAMA. 2002;287(12):1541–1547
doi:10.1001/jama.287.12.1541van Diepen S, Katz JN, Albert NM, et al. Contemporary management of cardiogenic shock: a scientific statement from the American Heart Association. Circulation. 2017;136(16):e232–e268
doi:10.1161/CIR.0000000000000525Thiele H, Zeymer U, Neumann FJ, et al. Intraaortic balloon support for myocardial infarction with cardiogenic shock (IABP-SHOCK II). N Engl J Med. 2012;367(14):1287–1296
doi:10.1056/NEJMoa1208410De Backer D, Biston P, Devriendt J, et al. Comparison of dopamine and norepinephrine in the treatment of shock (SOAP II). N Engl J Med. 2010;362(9):779–789
doi:10.1056/NEJMoa0907118